Abbreviated (12‐hour) versus traditional (24‐hour) postpartum magnesium sulfate therapy in severe pre‐eclampsia

Maia, Sabina Bastos; Katz, Leila; Neto, Carlos Noronha; Caiado, Bárbara V.R.; Azevedo, Ana P.R.L.; Amorim, Melânia Maria Ramos

doi:10.1016/j.ijgo.2014.03.024

Cited by 26 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study carried out by Darngawn et al [15] in Christian Medical College, Vellore showed that in case of severe preeclampsia a shortened (6-hour) MgSO4 regime was as effective as the 24-hour regime with significant benefits in terms of cost and morbidity [15]. A recent study in Brazil by Maia et al [16] showed that abbreviated exposure (12 hour) to MgSO4 in severe preeclampsia was associated with decreased drug exposure and reduced time-gap to contact newborn after delivery but similar outcomes [16].…”

Section: Discussionmentioning

confidence: 98%

Single Loading Dose of Magnesium Sulphate in Severe Preeclampsia and Eclampsia-Is it Effective? A Randomized Prospective Study

Dasgupta¹,

Sarkhel²,

Jain³

2015

OGIJ

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Single Loading Dose of Magnesium Sulphate in Severe Preeclampsia and Eclampsia-Is it Effective? A Randomized Prospective Study

Dasgupta¹,

Sarkhel²,

Jain³

2015

OGIJ

View full text Add to dashboard Cite

“…Only six trials (10%) were prospectively registered with the International Clinical Trials Registry Platform. 27,37,43,51,54,58 Two registry entries made reference to the collection of harms or adverse reactions stating 'safety and toleration' and 'possible side effects and intolerance' would be reported as secondary outcomes.…”

Section: Resultsmentioning

confidence: 99%

Inadequate safety reporting in pre‐eclampsia trials: a systematic evaluation

Duffy

Hirsch

Pealing

et al. 2017

BJOG

View full text Add to dashboard Cite

show abstract

“…Thus, Maia and col in their series had noted a 100% efficacy rate in the prevention of eclampsia [13]. As for Bourret et al, efficacy was 95% in the secondary prevention of eclampsia [12].…”

Section: Therapeutic Aspectsmentioning

confidence: 91%

“…It is the same in the studies of Omu in Kuwait, Bourretin France and Maia in Brazil [11][12][13]. On the other hand, the Pritchard protocol was the one prescribed in Nigeria [14].…”

Section: Therapeutic Aspectsmentioning

confidence: 99%

Use of Magnesium Sulphate in the Management of Severe Preeclampsia at the Centre University Hospital of Mother and Child (CHU-MEL) Cotonou Benin

Ja¹,

Mshs²,

Aboubakar³

et al. 2017

Gynecol Obstet

View full text Add to dashboard Cite

Objectives: To evaluate professionals practices and the contribution of magnesium sulphate in a better medical care for persons with severe preeclampsia at CHU-MEL. Materials and Method:We conducted a retrospective and cross-sectional study with the aim come up with a descriptive and analytical paper. Our study was conducted from January 15th, 2015 to July 15th, 2016, i.e. during eighteen (18) months. The sampling was exhaustive. The population was made of all patients admitted for severe preeclampsia with or without complications. Confidentiality requirements were met and informed consent obtained from all subjects. For the analytical study, the chi-square test was used and the difference was statistically significant with a p-value inferior than 0.05. Results:The prevalence of preeclampsia during the study period was 7.70% (447/5805 deliveries). Out of the 312 files that we were able to find and exploit, 272 revealed that patients were administrated a dose of magnesium sulphate, at a frequency estimated at 87.18%. Irregularities were noted in the protocol implementation: the maintenance dose was administered in 30% of cases, as a slow infusion (66.33%), for less than 24 hours in 37.24% of cases, and under supervision only in 22.62% of cases. Primary and secondary prevention of eclampsia was achieved in 98.5% and 80% of cases, respectively. Respecting the duration of treatment significantly reduces the onset and recurrence of seizures (p=0.003 and p=0.004). Decreased reflexes and respiratory distress were noted in 34.78% and in 8.7% of cases respectively. The maternal lethality rate was 1.34% and the stillbirth rate was 11.40%. Conclusion:Magnesium sulphate intake is undeniable in dealing with severe preeclampsia, but this solution/ drug is misused at the CHU-MEL. Appropriate solutions must therefore be taken in the execution and monitoring of the protocol.

show abstract

Abbreviated (12‐hour) versus traditional (24‐hour) postpartum magnesium sulfate therapy in severe pre‐eclampsia

Abstract: clinicaltrials.gov NCT1408979.

Cited by 26 publications

References 20 publications

Single Loading Dose of Magnesium Sulphate in Severe Preeclampsia and Eclampsia-Is it Effective? A Randomized Prospective Study

Single Loading Dose of Magnesium Sulphate in Severe Preeclampsia and Eclampsia-Is it Effective? A Randomized Prospective Study

Inadequate safety reporting in pre‐eclampsia trials: a systematic evaluation

Use of Magnesium Sulphate in the Management of Severe Preeclampsia at the Centre University Hospital of Mother and Child (CHU-MEL) Cotonou Benin

Contact Info

Product

Resources

About